TY  - JOUR
A1  - Gökbuget, Nicola
A1  - Zugmaier, Gerhard
A1  - Dombret, Hervé
A1  - Stein, Anthony
A1  - Bonifacio, Massimiliano
A1  - Graux, Carlos
A1  - Faul, Christoph
A1  - Brüggemann, Monika
A1  - Taylor, Kate
A1  - Mergen, Noemi
A1  - Reichle, Albrecht
A1  - Horst, Heinz August
A1  - Havelange, Violaine
A1  - Topp, Max S.
A1  - Bargou, Ralf C.
T1  - Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia
T2  - Leukemia and lymphoma
N2  - Minimal residual disease (MRD) is the strongest predictor of relapse in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). In BLAST study (NCT01207388), adults with BCP-ALL in remission with MRD after chemotherapy received blinatumomab, a CD19 BiTE® immuno-oncotherapy, 15 µg/m2/day for up to four 6-week cycles (4 weeks continuous infusion, 2 weeks off). Survival was evaluated for 110 patients, including 74 who received HSCT in continuous complete remission. With a median follow-up of 59·8 months, median survival (months) was 36·5 (95% CI: 22.0–not reached [NR]). Median survival was NR (29.5–NR) for complete MRD responders (n = 84) and 14.4 (3.8–32.3) for MRD non-responders (n = 23; p = 0.002); after blinatumomab and HSCT, median survival was NR (25.7–NR) (n = 61) and 16.5 (1.1–NR) (n = 10; p = 0.065), respectively. This final analysis suggests complete MRD response during blinatumomab treatment is curative. Post-hoc analysis of study data suggests while post blinatumomab HSCT may be beneficial in appropriate patients, long-term survival without HSCT is also possible.
KW  - Acute lymphoblastic leukemia
KW  - minimal residual disease
KW  - allogeneic hematopoietic stem cell transplantation
KW  - blinatumomab
KW  - immuno-oncotherapy
Y1  - 2020
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/62566
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-625663
SN  - 1029-2403
N1  - This trial was funded by Amgen Inc. Qualified researchers may request data from Amgen clinical trials. Complete details are available at http://www.amgen.com/datasharing. Xiaoyu Dong (Amgen Inc.) supported the data analyses. Jonathan Latham of PharmaScribe, LLC (on behalf of Amgen Inc.) and Beatrice Chiang, an employee of Amgen Inc, provided medical writing and editing assistance. Robert Dawson of CACTUS Communications Inc. (on behalf of Amgen Inc.) edited and formatted the figures.
VL  - 61
IS  - 11
SP  - 2665
EP  - 2673
PB  - Taylor & Francis Group
CY  - London [u.a.]
ER  -